Trial Profile
PET/CT imaging and dosimetry as predictive factors for treatment response of the 177Lu-DOTA-TATE therapy - DOTADOSE
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Jan 2019
Price :
$35
*
At a glance
- Drugs Lutetium-(177Lu)-oxodotreotide (Primary)
- Indications Neuroendocrine tumours
- Focus Therapeutic Use
- Acronyms DOTADOSE
- 26 Nov 2012 New trial record